Printer Friendly Version

Send to a Friend

Xcyte Therapies has broken ground on a new $4 million manufacturing facility in Bothell, Wash. The Seattle-based biotech will manufacture its most advanced product, Xcellerated T Cells, in the new facility, which could make enough T Cells to use in clinical trials beginning in 2005. The plant will potentially manufacture T Cells to treat up to 18,000 patients annually.